Murakawa Masaaki, Aoyama Toru, Miyagi Yohei, Kobayashi Satoshi, Ueno Makoto, Morimoto Manabu, Numata Masakatsu, Yamamoto Naoto, Tamagawa Hiroshi, Yukawa Norio, Rino Yasushi, Masuda Munetaka, Morinaga Soichiro
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Department of Surgery, Yokohama City University.
J Cancer. 2019 Jan 1;10(3):627-633. doi: 10.7150/jca.28660. eCollection 2019.
The predictive roles of secreted protein acidic and rich in cysteine (SPARC) in pancreatic ductal adenocarcinoma (PDAC) patients after curative resection have not been clarified. We investigated the correlations between the SPARC expression and the postoperative prognosis. We retrospectively analyzed the clinical data from consecutive patients who underwent curative resection for pancreatic cancer in our institution from 2005 to 2014. Stromal SPARC expression was analyzed by immunohistochemistry on tumor tissue microarrays (TMAs) from the patients. A total of 179 patients were enrolled to this study. The median follow-up period of the present study was 62.1 months. Seventy patients had positive SPARC expression (39.1%). There were no significant differences between the positive SPARC-positive group and the SPARC-negative group. In the survival analysis, there was a significant difference between the SPARC-positive and SPARC-negative groups in the 5-year overall survival (OS) rates after surgery, which were 8.1% and 19.8%, respectively (p=0.0316). A univariate analysis showed that the SPARC expression, size of tumor, lymph node metastasis, and residual tumor were possible prognostic factors. A multivariate analysis showed that the SPARC expression (hazard ratio [HR]: 1.44, 95% confidence interval [CI]: 1.017-2.051), lymph node metastasis (HR: 2.019, 95% CI: 1.318-3.091), and residual tumor (HR: 1.648, 95% CI: 1.132-2.401) were independent prognostic factors. The stromal SPARC expression in resectable pancreatic cancer patients might be useful as a prognostic marker.
富含半胱氨酸的酸性分泌蛋白（SPARC）在胰腺癌根治性切除术后患者中的预测作用尚未明确。我们研究了SPARC表达与术后预后之间的相关性。我们回顾性分析了2005年至2014年在本机构接受胰腺癌根治性切除的连续患者的临床资料。通过免疫组织化学方法对患者肿瘤组织微阵列（TMA）上的基质SPARC表达进行分析。本研究共纳入179例患者。本研究的中位随访期为62.1个月。70例患者SPARC表达阳性（39.1%）。SPARC阳性组和SPARC阴性组之间无显著差异。在生存分析中，SPARC阳性组和SPARC阴性组术后5年总生存率（OS）存在显著差异，分别为8.1%和19.8%（p = 0.0316）。单因素分析显示，SPARC表达、肿瘤大小、淋巴结转移和残留肿瘤可能是预后因素。多因素分析显示，SPARC表达（风险比[HR]：1.44，95%置信区间[CI]：1.017 - 2.051）、淋巴结转移（HR：2.019，95% CI：1.318 - 3.091）和残留肿瘤（HR：1.648，95% CI：1.132 - 2.401）是独立的预后因素。可切除胰腺癌患者的基质SPARC表达可能作为一种预后标志物。
